Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency.

Bone age Children Different doses Growth hormone deficiency Polyethylene glycol recombinant human growth hormone

Journal

World journal of clinical cases

ISSN: 2307-8960

Titre abrégé: World J Clin Cases

Pays: United States

ID NLM: 101618806

Informations de publication

Date de publication:
06 Oct 2023

Historique:

received: 12 07 2023

revised: 03 08 2023

accepted: 04 09 2023

medline: 30 10 2023

pubmed: 30 10 2023

entrez: 30 10 2023

Statut: ppublish

Résumé

With the improvement of economy and living standards, the attention paid to short stature in children has been increasingly highlighted. Numerous causes can lead to short stature in children, among which growth hormone deficiency (GHD) is a significant factor. To investigate the long-term efficacy and safety of different doses of long-acting polyethylene glycol recombinant human growth hormone (PEG-rhGH) in the treatment of GHD in children. We selected 44 pediatric patients diagnosed with GHD who were treated at Wuhu First People's Hospital from 2014 to 2018. Total 23 patients were administered a high dose of long-acting PEG-rhGH at 0.2 mg/kg subcutaneously each week, forming the high-dose group. Meanwhile, 21 patients were given a lower dose of long-acting PEG-rhGH at 0.14 mg/kg subcutaneously each week, establishing the low-dose Group. The total treatment period was 2 years, during which we monitored the patients' height, annual growth velocity (GV), height standard deviation score (HtSDS), chronological age (CA), bone age (BA), and serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) before treatment and at 6 mo, 1 year, and 2 years after treatment initiation. We also monitored thyroid function, fasting plasma glucose, fasting insulin, and other side effects. Furthermore, we calculated the homeostatic model assessment for insulin resistance. After 1 year of treatment, the GV, HtSDS, IGF-1, BA, and IGFBP-3 in both groups significantly improved compared to the pre-treatment levels ( The use of PEG-rhGH in treating GHD patients was confirmed to be effective, with similar outcomes observed in both the high-dose group and low-dose groups, and no significant differences in the main side effects.

Sections du résumé

BACKGROUND BACKGROUND

AIM OBJECTIVE

To investigate the long-term efficacy and safety of different doses of long-acting polyethylene glycol recombinant human growth hormone (PEG-rhGH) in the treatment of GHD in children.

METHODS METHODS

We selected 44 pediatric patients diagnosed with GHD who were treated at Wuhu First People's Hospital from 2014 to 2018. Total 23 patients were administered a high dose of long-acting PEG-rhGH at 0.2 mg/kg subcutaneously each week, forming the high-dose group. Meanwhile, 21 patients were given a lower dose of long-acting PEG-rhGH at 0.14 mg/kg subcutaneously each week, establishing the low-dose Group. The total treatment period was 2 years, during which we monitored the patients' height, annual growth velocity (GV), height standard deviation score (HtSDS), chronological age (CA), bone age (BA), and serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) before treatment and at 6 mo, 1 year, and 2 years after treatment initiation. We also monitored thyroid function, fasting plasma glucose, fasting insulin, and other side effects. Furthermore, we calculated the homeostatic model assessment for insulin resistance.

RESULTS RESULTS

After 1 year of treatment, the GV, HtSDS, IGF-1, BA, and IGFBP-3 in both groups significantly improved compared to the pre-treatment levels (

CONCLUSION CONCLUSIONS

The use of PEG-rhGH in treating GHD patients was confirmed to be effective, with similar outcomes observed in both the high-dose group and low-dose groups, and no significant differences in the main side effects.

Identifiants

DOI: 10.12998/wjcc.v11.i28.6715 PMID: 37901029 PMC: PMC10600835

pubmed: 37901029

doi: 10.12998/wjcc.v11.i28.6715

pmc: PMC10600835

doi:

Types de publication

Journal Article

Langues

eng

Pagination

6715-6724

Informations de copyright

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors declare no conflicts of interest for this article.

Références

Endocr Rev. 2014 Jun;35(3):376-432

pubmed: 24450934

Front Endocrinol (Lausanne). 2019 Sep 19;10:638

pubmed: 31616374

J Clin Med. 2021 Oct 30;10(21):

pubmed: 34768618

Nutrients. 2019 Dec 07;11(12):

pubmed: 31817909

J Biomed Sci. 2019 Nov 7;26(1):91

pubmed: 31699087

Cochrane Database Syst Rev. 2013 Jun 05;(6):CD008901

pubmed: 23737090

J Clin Endocrinol Metab. 2006 Jun;91(6):2047-54

pubmed: 16537676

Eur J Endocrinol. 2022 Oct 13;187(5):709-718

pubmed: 36130048

Int J Endocrinol. 2019 Sep 19;2019:1438723

pubmed: 31641350

Front Endocrinol (Lausanne). 2017 Nov 20;8:313

pubmed: 29209274

J Clin Res Pediatr Endocrinol. 2008;1(1):30-7

pubmed: 21318062

Horm Res Paediatr. 2016;86(6):361-397

pubmed: 27884013

Diabetol Metab Syndr. 2013 Nov 15;5(1):71

pubmed: 24228769

Growth Horm IGF Res. 2015 Dec;25(6):286-93

pubmed: 26363846

Horm Metab Res. 2014 Mar;46(3):219-23

pubmed: 24297484

Endocrine. 2019 Jul;65(1):25-34

pubmed: 31119649

Drug Des Devel Ther. 2015 Dec 18;10:13-21

pubmed: 26719670

Endocrine. 2018 Mar;59(3):643-650

pubmed: 28875423

Pediatr Endocrinol Diabetes Metab. 2010;16(1):39-43

pubmed: 20529605

Eur J Endocrinol. 2016 Jun;174(6):C1-8

pubmed: 27009113

J Clin Endocrinol Metab. 2020 Apr 1;105(4):

pubmed: 32022863

PLoS One. 2018 Oct 24;13(10):e0206009

pubmed: 30356273

Horm Res Paediatr. 2019;92(3):150-156

pubmed: 31707392

Front Endocrinol (Lausanne). 2021 Nov 25;12:779365

pubmed: 34899612

Diabetologia. 1985 Jul;28(7):412-9

pubmed: 3899825

J Clin Endocrinol Metab. 2013 Jan;98(1):352-61

pubmed: 23162104

Eur J Endocrinol. 2009 Oct;161(4):533-40

pubmed: 19654233

Mar Drugs. 2023 Feb 03;21(2):

pubmed: 36827152